Avalyn Pharma is led by CEO Lyn Baranowski, who previously worked at Pearl Therapeutics, where she helped develop treatments ...
Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...
Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...
Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...
Avalyn Pharma (AVLN) stock will be in focus as the company files for a Nasdaq IPO to fund clinical studies for its inhaled ...
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for respiratory diseases, filed for a US initial public offering.The Boston-based company’s pipeline is focused on treating ...
In what shakes out to be the largest follow-on stock offering in biopharma history, Revolution Medicines Inc., an oncology company that was the subject of buyout rumors earlier this year, priced 10.56 ...
Peer-reviewed study confirming strong predictive performance of patient-specific lung digital twins, validated against ...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been ...
Cautionary Language Concerning Forward-Looking Statements ...
Cipla's nintedanib capsules are the generic of Boehringer Ingelheim’s Ofev. IPF is a chronic, progressive lung disease characterized by irreversible scarring of lung tissue, leading to declining lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results